$50,000 of PTC THERAPEUTICS INC. lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025."
You can find more data on corporate lobbying on Quiver Quantitative.
PTCT Insider Trading Activity
PTCT insiders have traded $PTCT stock on the open market 157 times in the past 6 months. Of those trades, 0 have been purchases and 157 have been sales.
Here’s a breakdown of recent trading of $PTCT stock by insiders over the last 6 months:
- NEIL GREGORY ALMSTEAD (CHIEF TECHNICAL OPS OFFICER) has made 0 purchases and 36 sales selling 165,851 shares for an estimated $12,744,900.
- ERIC PAUWELS (CHIEF BUSINESS OFFICER) has made 0 purchases and 32 sales selling 114,339 shares for an estimated $7,940,361.
- MARK ELLIOTT BOULDING (EXEC. VP AND CLO) has made 0 purchases and 42 sales selling 96,401 shares for an estimated $6,265,482.
- EMMA REEVE has made 0 purchases and 19 sales selling 75,733 shares for an estimated $5,163,979.
- ALLAN STEVEN JACOBSON has made 0 purchases and 12 sales selling 39,667 shares for an estimated $2,995,618.
- MATTHEW B. KLEIN (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 6 sales selling 32,935 shares for an estimated $2,268,719.
- GLENN JR MD PHD STEELE sold 12,000 shares for an estimated $916,199
- DAVID P SOUTHWELL sold 12,000 shares for an estimated $700,080
- PIERRE GRAVIER (CHIEF FINANCIAL OFFICER) has made 0 purchases and 2 sales selling 4,655 shares for an estimated $289,037.
- CHRISTINE MARIE UTTER (SVP, CHIEF ACCOUNTING OFFICER) has made 0 purchases and 3 sales selling 3,650 shares for an estimated $280,968.
- LEE SCOTT GOLDEN (EVP & CHIEF MEDICAL OFFICER) has made 0 purchases and 3 sales selling 2,848 shares for an estimated $219,060.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
PTCT Hedge Fund Activity
We have seen 155 institutional investors add shares of PTCT stock to their portfolio, and 139 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JEFFERIES FINANCIAL GROUP INC. added 1,584,678 shares (+inf%) to their portfolio in Q3 2025, for an estimated $97,251,688
- ARMISTICE CAPITAL, LLC removed 1,458,192 shares (-30.8%) from their portfolio in Q3 2025, for an estimated $89,489,243
- POINT72 ASSET MANAGEMENT, L.P. added 1,220,642 shares (+inf%) to their portfolio in Q3 2025, for an estimated $74,910,799
- CITADEL ADVISORS LLC added 810,532 shares (+88.1%) to their portfolio in Q3 2025, for an estimated $49,742,348
- TORONTO DOMINION BANK added 800,567 shares (+32.7%) to their portfolio in Q3 2025, for an estimated $49,130,796
- SG AMERICAS SECURITIES, LLC added 764,364 shares (+587.5%) to their portfolio in Q4 2025, for an estimated $58,061,089
- MORGAN STANLEY removed 743,922 shares (-63.9%) from their portfolio in Q3 2025, for an estimated $45,654,493
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
PTCT Analyst Ratings
Wall Street analysts have issued reports on $PTCT in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 08/20/2025
- Morgan Stanley issued a "Overweight" rating on 08/20/2025
- Wells Fargo issued a "Overweight" rating on 08/20/2025
- UBS issued a "Buy" rating on 07/29/2025
- Truist Securities issued a "Buy" rating on 07/29/2025
- Cantor Fitzgerald issued a "Overweight" rating on 07/29/2025
To track analyst ratings and price targets for PTCT, check out Quiver Quantitative's $PTCT forecast page.
PTCT Price Targets
Multiple analysts have issued price targets for $PTCT recently. We have seen 13 analysts offer price targets for $PTCT in the last 6 months, with a median target of $76.0.
Here are some recent targets:
- Brian Abrahams from RBC Capital set a target price of $91.0 on 12/01/2025
- Gena Wang from Barclays set a target price of $68.0 on 11/06/2025
- Benjamin Burnett from Wells Fargo set a target price of $93.0 on 11/05/2025
- Geoff Meacham from Citigroup set a target price of $75.0 on 11/05/2025
- Joseph Thome from TD Cowen set a target price of $63.0 on 11/05/2025
- Paul Choi from Goldman Sachs set a target price of $50.0 on 11/05/2025
- Kelly Shi from Jefferies set a target price of $77.0 on 10/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
